Skip to search formSkip to main contentSkip to account menu

sepantronium bromide

Known as: 1H-Naphth(2,3-d)imidazolium, 4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazinylmethyl)-, Bromide 
A small-molecule proapoptotic agent with potential antineoplastic activity. Sepantronium bromide selectively inhibits survivin expression in tumor… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

YM-155
survivin inhibitor YM155

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Sepantronium Bromide (YM155), A Small Molecule Survivin Inhibitor, Promotes Apoptosis by Induction of Oxidative Stress, Worsens the Behavioral Deficits and Develops an Early Model of Toxic…
Cuprizone (cup) model targets oligodendrocytes (OLGs) degeneration and is frequently used for the mechanistic understanding of de… 
2018
2018
Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells
Sepantronium bromide (YM155), originally developed against the anti-apoptotic protein survivin, performed exceptionally well in… 
2018
2018
Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
Sepantronium bromide (YM155) is a hydrophilic quaternary compound that cannot be administered orally due to its low oral… 
2016
2016
Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors
Treatments for retinoblastoma (Rb) vary depending on the size and location of the intraocular lesions and include chemotherapy… 
2015
2015
Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
2014
2014
Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
2014
2014
Title: Targeting Survivin with YM155 (sepantronium bromide): A novel therapeutic strategy for paediatric acute myeloid leukemia
Word Count: 200 20 
2013
2013
Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
2013
2013
The Survivin Suppressant YM155 (Sepantronium Bromide) Has Potent Pre-Clinical Activity Against Pediatric Acute Myeloid Leukemia
Despite aggressive chemotherapy and a high remission induction rate, approximately one third of children with acute myeloid… 
2012
2012
A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible for or Have Previously…
Abstract 2731 Background: Survivin is responsible for preservation of cell viability and regulation of mitosis in tumor cells… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)